Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
- PMID: 36155249
- DOI: 10.1016/j.cgh.2022.09.015
Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
Comment in
-
Reply.Clin Gastroenterol Hepatol. 2023 Aug;21(9):2431-2432. doi: 10.1016/j.cgh.2022.11.006. Epub 2022 Nov 17. Clin Gastroenterol Hepatol. 2023. PMID: 36402373 No abstract available.
Comment on
-
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.Clin Gastroenterol Hepatol. 2023 Aug;21(9):2338-2346.e3. doi: 10.1016/j.cgh.2022.08.011. Epub 2022 Aug 17. Clin Gastroenterol Hepatol. 2023. PMID: 35987302
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources